Improved secretion of molecular chaperone-assisted human IgG in silkworm, and no alterations in their N-linked glycan structures

著者	Dojima Takashi, Nishina Takuya, Kato Tatsuya, Uno Tsuyoshi, Yagi Hirokazu, Kato Koichi, Ueda Hiroshi, Park Enoch Y.
journal or publication title	Biotechnology Progress
volume	26
number	1
page range	232-238
year	2009-11-13
出版者	Wiley
権利	Copyright (C) 2009 American Institute of Chemical Engineers (AIChE) Copyright (C) 1999-2015 John Wiley & Sons, Inc. All Rights Reserved. The definitive version is available at www.blackwell-synergy.com
URL	http://hdl.handle.net/10297/9040

doi: 10.1002/btpr.313

Improved Secretion of Molecular Chaperone-assisted Human IgG in Silkworm, and No Alterations in their N-Linked Glycan Structures

Takashi Dojima,¹ Takuya Nishina,² Tatsuya Kato,² Tsuyoshi Uno,³ Hirokazu Yagi,^{3,4} Koichi Kato^{3,5,6,7}, Hiroshi Ueda⁸ and Enoch Y. Park^{1,2*}

Integrated Bioscience Section, Graduate School of Science and Technology, Shizuoka University, 836 Ohya Suruga-ku, Shizuoka 422-8529, Department of Applied Biological Chemistry, Shizuoka University, 836 Ohya Suruga-ku, Shizuoka 422-8529, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, National Institute for Physiological Sciences, Institute for Molecular Science and Okazaki Institute for Integrative Bioscience, National Institutes of Natural Science, 5-1 Higashiyama Myodaiji, Okazaki 444-8787, GLYENCE Co., Ltd., 2-22-8 Chikusa, Chikusa-ku, Nagoya 464-0858, The Glycoscience Institute, Ochanomizu University, 2-1-1 Ohtsuka, Bunkyo-ku, Tokyo 112-8610, and Department of Chemistry and Biotechnology, School of Engineering, University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan

Authors' e-mail addresses: takashidojima@yahoo.co.jp; nishina9110@yahoo.co.jp; actkato@agr.shizuoka.ac.jp; p992049@phar.nagoya-cu.ac.jp; "kkato"@phar.nagoya-cu.ac.jp; hueda@chembio.t.u-tokyo.ac.jp; acypark@ipc.shizuoka.ac.jp

* To whom correspondence should be addressed. Phone & Fax. +81-54-238-4887. E-mail: acypark@ipc.shizuoka.ac.jp.

¹ Integrated Bioscience Section, Graduate School of Science and Technology, Shizuoka University

² Department of Applied Biological Chemistry, Shizuoka University

³ Graduate School of Pharmaceutical Sciences, Nagoya City University

⁴ National Institute for Physiological Sciences

⁵ Institute for Molecular Science and Okazaki Institute for Integrative Bioscience, National Institutes of Natural Science

⁶ GLYENCE Co., Ltd.

⁷ The Glycoscience Institute

⁸ Department of Chemistry and Biotechnology, School of Engineering, University of Tokyo

Abstract. Human 29IJ6 IgG was expressed in silkworm using a *Bombyx mori* nucleopolyhedrovirus (BmNPV) bacmid system. The mean amounts of 296IJ6 IgG produced in larval hemolymph and whole pupae were 30.1 µg/larva and 78.0 µg/pupa, respectively. The use of molecular chaperones including calreticulin (CRT), calnexin (CNX) and immunoglobulin heavy chain binding protein (BiP, GRP78) improved the production of 296IJ6 IgG secretion in the larvae fivefold. The total yield of recombinant 29IJ6 IgG was 239 µg/ml when coexpressed with CRT. However, the overexpression of molecular chaperones had negative effects on secretion. The *N*-linked glycans of secreted 296IJ6 IgG in silkworm hemolymph were dominated by paucimannose structures. Small amounts of GlcNAc residues linked to the Man α 1,3 branch were detected. When molecular chaperones were coexpressed, the compositions of *N*-linked glycans in the IgG1 produced were unchanged compared with those produced without them. This suggests that *N*-glycosylation is controlled by a regulatory function in the Golgi apparatus even though the translation of 296IJ6 IgG was assisted by coexpression of molecular chaperones. Therefore, if the glycosylation pathways that coexpress *N*-acetylglucosaminyltransferase, galactosyltransferase and sialyltransferase could be improved, silkworm larvae might prove a useful system for producing human antibodies.

KEYWORDS: silkworm larvae, molecular chaperone, antibody, bacmid, *N*-glycan

Introduction

Currently licensed therapeutic antibodies are produced by mammalian cell culture using Chinese Hamster ovary (CHO) cells, or mouse NS0 or Sp2/0 plasma cell lines (1). The increasing demand for monoclonal antibodies (mAbs) with regards to amount and quality have led to the development of a variety of recombinant protein production systems, such as yeast, insect and mammalian cell lines, and transgenic plants and animals (2).

Silkworm larvae are useful and cost-effective hosts in terms of the amount of protein production that can be achieved. A high level of recombinant gene expression is made possible by the commonly used strong polyhedrin and p10 promoters, in which host cells have to translate and produce large amounts of heterologous protein within a short time. However, host protein synthesis can be shut down by baculovirus infections, which may lead to a limitation in the supply of secretory assistance factors (3, 4).

Improper secretory processing can be especially problematic by several days postinfection when the host cell's post-translational processing machinery has deteriorated (5). Because the cellular folding system is disrupted leading to an extensive aggregation and degradation of expressed protein, overall production is compromised. In fact, extensive aggregation was observed following IgG expression in insect cells driven by the strong polyhedrin promoter (6). To prevent these damaging events, insect cells and larvae require molecular chaperones to regulate and correct the folding, assembling and transition of proteins. Fortunately, this system can be applied for the coexpression of multiple proteins simultaneously.

During glycoprotein transportation from the endoplasmic reticulum (ER) to the Golgi apparatus (7–10), *N*-linked glycans are processed along the secretory pathway. The newly synthesized proteins in the ER each interact differently with molecular chaperones (11). Some of them interact at first with immunoglobulin heavy chain binding protein (BiP, GRP78) and then with calnexin (CNX) and calreticulin (CRT) (12). Otherwise, proteins in the ER bind to CNX and CRT but do not associate with BiP (13) or are sequentially associated with BiP and GRP94 (14). Furthermore, the formation of intramolecular disulfide bonds can be catalyzed by protein disulfide isomerase (PDI), by ERp57, or by both oxidoreductases acting together (15). The rules that govern such selection of differential chaperones are only poorly understood (11).

In this study, we investigated the *N*-linked glycosylation of IgG1 produced in silkworm larvae and pupae using a *Bombyx mori* nucleopolyhedrovirus (BmNPV) bacmid system. IgG1 was produced by coexpression with five molecular chaperones: CNX, CRT, ERp57, BiP and Hsp70. These molecular chaperones are susceptibility factor for IgG1 production in silkworm larvae. It is crucial to assure the consistency and reproducibility of protein synthesis, not only in terms of protein sequence and bioactivity, but also in terms of post-translational modifications (16). Each secreted IgG1 was purified and *N*-linked glycan structures were compared using high performance liquid chromatography (HPLC) mapping.

88

Materials and Methods

89 **Silkworm larvae, pupae and bacmids.** *Bombyx mori* fifth-instar silkworm larvae
90 and pupae (Fuyoutsukubane, Ehime Sansyu, Yahatahama, Japan) were used in this
91 study. The larvae were reared on an artificial diet (Silkmate 2S, Nihon Nosan,
92 Yokohama, Japan) in an incubator at 25 °C.

93 The recombinant cysteine protease- and chitinase-deficient BmNPV containing the
94 29IJ6 IgG gene (rBmNPV-*CP*⁻*Chi*⁻/29IJ6 IgG) bacmid was used for IgG1 expression
95 (17). The 29IJ6VH-C γ and 29IJ6VL-C λ genes are controlled by a polyhedrin promoter
96 and a p10 promoter, respectively. To secret expressed protein into the silkworm larval
97 hemolymph, the signal sequence from bombyxin (*bx*) was added to the *N*-termini of
98 both heavy and light chain genes. The molecular chaperones CNX, CRT, ERp57, BiP
99 and Hsp70 were expressed under the *ie*-2 promoter. Recombinant cysteine
100 protease-deficient BmNPV (rBmNPV(*ie*)-*CP*⁻) bacmids containing each chaperone
101 were prepared as described (18).

102 **29IJ6 IgG expression in silkworm larvae and pupae.** The rBmNPV bacmid
103 DNAs were injected directly into the first day of fifth-star larvae and pupae of
104 silkworm. Fifty micrograms of rBmNPV bacmid was suspended in 5 μ l of
105 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE)-C
106 (Invitrogen, Carlsbad, CA, USA) as a transfection reagent and placed at room
107 temperature for 45 min. The resulting mixture was diluted to a final volume of 50 μ l
108 with phosphate buffered saline (PBS) and 10 μ l of the bacmid mixture was then

109 injected into the dorsum using a syringe with a 26-gauge beveled needle. To express
110 proteins with chaperones, 22.5 μ l aliquots containing 10 μ g each of the
111 rBmNPV-*CP⁻Ch⁻*/29IJ6 IgG and rBmNPV(*ie*)-*CP⁻* bacmids expressing the chaperone
112 genes together with helper plasmids were injected.

113 The silkworm larvae and pupae were reared at 25 °C in a breeding incubator and
114 harvested at 6 days post-injection (d.p.i.). The silkworm larval hemolymph was
115 collected by cutting the caudal leg in a tube containing 5 μ l of 200 mM
116 1-phenyl-2-thiourea and centrifuged at 9055 g for 10 min at 4 °C. The supernatants
117 were immediately frozen at -80 °C for further analysis. The silkworm pupae were
118 collected and frozen in liquid nitrogen, then ground in a mortar and added to 3.4 ml of
119 homogenization buffer (20 mM sodium phosphate, 0.5 M NaCl, pH 7.0) and sonicated
120 on ice three times for 30 s each, with 30 s intervals, using a sonicator (VC130PB, Sonic
121 & Materials Inc., Newton, CT, USA). They were then centrifuged at 5500 g for 10 min.
122 The supernatant was filtered through 0.45 μ m nitrocellulose membrane filters
123 (Advantec, Tokyo, Japan) and used for further analysis. These experiments were
124 performed on 10 larvae or pupae each time and were repeated five times at different
125 time throughout one year. Data are reported as the mean and standard deviation.

126 **SDS-PAGE and western blot analysis.** The protein samples were analyzed using
127 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using the
128 Mini-PROTEANE II system (Bio-Rad, Hercules, CA, USA). The respective bands
129 were detected using Coomassie Brilliant Blue (CBB). For western blotting, the reduced

samples were boiled for 5 min before they were run on the SDS–PAGE gels. A mouse anti-human IgG (H+L) antibody (Jackson ImmunoResearch Lab., Inc. West Grove, PA, USA) was used as the primary antibody. The immunoblot bands were visualized using enhanced chemiluminescence (ECL) with western blotting detection reagents (GE Healthcare, Piscataway, NJ, USA) and analyzed using a Fluor-S/MAX multi-image (Bio-Rad). Magic Mark XP Western Protein Standard (Invitrogen) was used as a molecular weight marker. The protein concentration was measured using the Bradford method with a protein assay kit (Bio-Rad).

Quantification of 29IJ6 IgG. The expressed IgGS were quantified using the Human IgG enzyme linked immunosorbent assay (ELISA) quantification kit (Bethyl Lab. Inc., Montgomery, TX, USA). One hundred microliters per well of 10 µg/ml goat anti-human IgG affinity-purified solution was used as a coating antibody in a coating buffer containing 0.05 M carbonate-bicarbonate (pH 9.6). This was used to coat a 96-well flexible assay plate for 1 h at room temperature. Two hundred microliters of blocking solution (10% skimmed milk in 50 mM Tris-HCl 0.14 M NaCl, pH 8.0) was added to the antibody-coated plate well, followed by incubation for 30 min at room temperature. The wells were washed three times with washing solution (50 mM Tris-HCl, 0.14 M NaCl, 0.05% Tween 20, pH 8.0) and the diluted expressed protein was then added to the antibody-coated plate wells, incubated for 1 or 2 h at room temperature and washed three times with 200 µl of washing buffer. As a second antibody, 100 µl of goat anti-human IgG-horseradish peroxidase (HRP) conjugate

151 diluted 50,000–100,000 times in sample/conjugate diluent (50 mM Tris-HCl, 0.14 M
152 NaCl, 1% BSA, 0.05% Tween 20, pH 8.0), was added to each well, incubated for 1 h
153 and washed three times with 200 µl of washing buffer. One hundred microliters of
154 substrate (0.1 mg/ml 3,3',5,5'-tetramethylbenzidine, TMBZ, in 100 mM sodium acetate,
155 pH 6.0, with 0.2% v/v of 30% hydrogen peroxidase) was added to each well and left at
156 room temperature for blue color development. The reaction was stopped by the addition
157 of 50 µl of 2 M H₂SO₄ solution. The color developed was measured at optical densities
158 (ODs) of 450 and 655 nm. The value calculated by subtracting OD₄₅₀ from OD₆₅₀ was
159 used as a measure of the amount of 29IJ6 IgG. Human reference serum (4 mg/ml) was
160 used for the calibration of IgG as a standard.

161 **Purification of expressed 29IJ6 IgG from silkworm larval hemolymph and**
162 **pupae.** Samples of hemolymph from larvae and supernatants from pupal homogenates
163 were filtered with 0.45 µm nitrocellulose membrane filter and diluted fivefold with
164 buffer (20 mM sodium phosphate, 0.5 M NaCl, pH 7.0). The diluted sample was
165 applied to a HiTrap rProtein A FF column (5.0 ml bed volume, GE Healthcare)
166 according to the manufacture's protocol. The column was then subsequently eluted at
167 0.5-1.0 ml/min with elution buffer (0.1 M sodium citrate, pH 3.0). Chromatography
168 was carried out using an AKTA 10S unit controlled by UNICORN software version
169 5.11 (GE Healthcare). Fifteen milliliters of the eluate from the column was dialyzed
170 with 1 liter of pure water overnight and a dialyzed sample was lyophilized for 72 h.

171 **Structural analysis of N-linked glycans.** All experimental procedures used,

including the chromatographic conditions and glycosidase treatments, have been described previously (19–21). The purified IgG1 was further proteolyzed with chemotrypsin and trypsin mixture and then digested with glycoamidase A to release *N*-linked glycans. After removal of the peptide materials, the reducing ends of the *N*-linked glycans were derivatized with 2-aminopyridine (PA) (Wako Pure Chemical Ind., Ltd., Osaka, Japan). The mixture of PA-derivatives of the *N*-linked glycans was individually separated and identified sequentially on a TSK-gel Amide-80 HPLC column (Tosoh, Tokyo, Japan) and a Shim-pack HRC-ODS column (Shimadzu, Kyoto, Japan). The identification of *N*-linked glycan structures were based on their elution positions on two kinds of columns in comparison with PA-glycans in the GALAXY database (22). The *N*-glycans were confirmed by co-chromatography and matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy (MALDI-TOF-MS) (23).

Results

Comparison of 29IJ6 IgG expression levels in the larval hemolymph and pupae of silkworm, and *N*-linked glycan structures. The 29IJ6 IgG was expressed in the larval hemolymph and pupae of silkworm injected with 10 µg/larva of rBmNPV bacmid and reared for 6 days. The expressed 296IJ6 IgG levels in silkworm larvae and pupae were quantified using ELISA. The mean amounts of 296IJ6 IgG in larval hemolymph and whole pupae were 30.1 µg/larva and 78.0 µg/pupa, respectively.

The *N*-glycan structure from silkworm larval hemolymph contained Man₂GlcNAc(Fuc)GlcNAc (47.4%), Man₃GlcNAc(Fuc)GlcNAc (28.5%) and a small amount of GlcNAcMan₃GlcNAc(Fuc)GlcNAc (3.4%; Tables 1 and 2). In contrast, the *N*-linked glycan structure of 296IJ6 IgG in the whole pupae contained paucimannosidic glycans (52.1%) as in the hemolymph and 14.6% of a terminal GlcNAc residue. High mannose structures were expressed in the whole pupae (33.3%) as shown in Table 2. This suggested that proteins expressed from the whole pupae resulted from insufficient processing of *N*-linked glycans. It also suggested that the pupae had higher *N*-acetylglucosaminyltransferase activity than the larvae. Furthermore α1,6-fucose residues were attached to the 296IJ6 IgG expressed in silkworm larvae and pupae: this allergenic residue has not been detected before.

Human chaperone-assisted recombinant 29IJ6 IgG expression. Five kinds of molecular chaperones were used for coexpression to test for any enhancement of 29IJ6 IgG secretion. Coexpression of human chaperone with 29IJ6 IgG was performed by

injection of 10 µg of each of the rBmNPV bacmids into silkworm larvae. In all cases, secretion of heavy chain (HC) and light chain (LC) proteins in the hemolymph were identified by western blot analysis under reducing conditions (Fig. 1A). The fully assembled IgG (H₂L₂) was also detected as well as intermediate immunoglobulin oligomer assemblies (H₂L and H₂) under non-reducing conditions (Fig. 1B).

When CRT, CNX and BiP were coexpressed with 296IJ6 IgG in silkworm larvae, the amounts of secreted 296IJ6 IgG in larval hemolymph were increased significantly to 229, 220 and 119 µg/ml, respectively (Fig. 2). These levels were approximately 5-fold higher than those produced without coexpression of molecular chaperones (43.0 µg/ml). Coexpression levels of secreted 296IJ6 IgG with ERp57 or Hsp70 were 175 and 117 µg/ml, respectively, and these were 3–4-fold higher than controls. These results show that CRT, CNX and BiP had significant effects on 296IJ6 IgG folding and assembly in post-translational modification. The combined effects of CRT with the other molecular chaperones were also investigated. Levels of 296IJ6 IgG in the larval hemolymph were decreased notably in comparison with those seen using only CRT (Fig. 3).

Effect of calreticulin on recombinant 29IJ6 IgG expression. Coexpression of several proteins in silkworm larvae was easily achieved using the bacmid system and the expression level was assumed to be controlled by the amount of injected bacmid DNA. The expressions of 296IJ6 IgG and the molecular chaperone were controlled by the polyhedrin promoter and *ie-2*, respectively. There are great differences in

transcriptional levels between the polyhedrin and the *ie-2* promoters. The expression phase is also different in that the *ie-2* promoter works at an early stage of infection but the polyhedrin promoter works at a later stage (24). When the injection level of the CRT bacmid was increased from 5 to 100 µg/ml, the secreted IgG1 level decreased significantly from 239 to 16 µg/ml in the larval hemolymph (Fig. 4). This indicates that excessive CRT expression inhibited the secretion of IgG1. Intracellular trafficking of 296IJ6 IgG in silkworm larvae might require not only CRT but also other proteins for interaction, such as ERp57.

***N*-linked glycans in human chaperone-assisted recombinant 29IJ6 IgG.**

N-linked glycan structure was analyzed for the purified secreted 296IJ6 IgG coexpressing molecular chaperones. The compositions of *N*-linked glycan were Man α 1,3(Man α 1,6)Man β 1,4GlcNAc β 1,4(Fuc α 1,6)GlcNAc, Man α 1,6Man β 1,4GlcNAc β 1,4(Fuc α 1,6)GlcNAc and GlcNAc β 1,2Man α 1,3(Man α 1,6)Man β 1,4GlcNAc β 1,4(Fuc α 1,6)GlcNAc (Table 1). In all cases, there were few differences in *N*-linked glycan structure regardless of the molecular chaperone used (Table 2). Man α 1,6Man β 1,4GlcNAc β 1,4(Fuc α 1,6)GlcNAc (a in Table 1) and Man α 1,3(Man α 1,6)Man β 1,4GlcNAc β 1,4(Fuc α 1,6)GlcNAc (b in Table 1) were predominant in the silkworm larvae hemolymph (Table 2). In addition, small amounts of GlcNAc residue linked to the Man α 1,3 branch were detected. The *N*-linked glycan profile is affected by manufacturing conditions such as the culture medium used, the efficiency of protein expression and the physiological status of the

host cell (25, 26). However, we found that these molecular chaperones did not affect *N*-glycosylation in this expression system.

Discussion

Rahman and Gopinathan (27) described the infection process of BmNPV. *B. mori* has an “open circulatory system” so the fat bodies and other tissues lie submerged in hemolymph within the larvae. Several proteins synthesized in the fat bodies consequently get leached out into the hemolymph without actually depending on the secretory process. This will be enhanced following viral infection because BmNPV multiplication is maximal in the fat bodies. After virus infection the fat body cells are lysed in significant numbers, leading to the leaching of the proteins into hemolymph. This was also shown when using BmNPV bacmids containing a viral protease: more than 90% of total protein was detected in the hemolymph of silkworm larvae (28). However, the secreted proteins appear to be especially susceptible to intracellular aggregation because of the complexity of the secretion pathway. It has been reported that secreted levels of expressed protein can be 10 to 100 times lower than intracellular levels (29). Most newly synthesized proteins are aggregated and degraded or misfolded because of the inadequacy of post-translational modifications. However, when a cysteine protease-deficient BmNPV (BmNPV-CP⁻) bacmid was transfected into silkworm larvae, only 30% of the protein was secreted into the hemolymph and the rest remained in the fat body (30). This resulted from delayed fat body cell lysis because of deletion of the viral protease.

Post-translational modification is effected by molecular chaperones in the ER for folding and assembly, followed by glycan processing in the Golgi apparatus. Protein folding and assembly within cells is a complex process with stringent quality control mechanisms (31), which is largely regulated by enzymes and an array of molecular chaperones. This is why we used the BmNPV-CP-*Ch⁻* bacmid for investigating the *N*-linked glycan structures of human IgG.

Previously, we have demonstrated efficient heterologous protein production in insect cells and larvae (32–34) and a human antibody has been expressed in silkworm larvae (17). Human IgG antibodies are composed of two identical heavy chain polypeptides (MW ~25 kDa) and two identical light chain polypeptides (~50 kDa) that oligomerize to form a heterotetramer (~150 kDa) (35). The limiting process of mAb production is likely to be the phase of folding and assembly in the ER, mediated by the sequential interactions of HC and LC polypeptide (36).

Here we demonstrated that an *N*-linked glycan in IgG1 protein could be produced by silkworm larval hemolymph and pupae. Levels expressed in the pupae were higher than in the larval hemolymph. However, it is difficult to collect pupal hemolymph because it is thick and sticky. Therefore, whole pupae were used for the analysis of IgG1 expression levels and the composition of the *N*-linked glycans. In whole pupae, the trimannosyl core structure made up 30% of the *N*-linked glycans (Table 2). Additionally, 14.6% of terminal GlcNAc residues were found linked to the Man α 1,3 branch. This indicates that the pupal activity of a specific *N*-acetylglucosaminidase was higher than in larvae. The other residues, accounting for 33.3%, were predominantly

high mannose-containing structures. In contrast, the *N*-linked glycans of larvae were predominantly of a paucimannose type, with small amounts of GlcNAc residues linked to the Man α 1,3 branch.

Immunoglobulin assembly occurs during movement through the ER lumen and is followed by trafficking of the native mAb through the Golgi apparatus followed by secretion (37). The glycoproteins of newly synthesized proteins act as signals for enhanced folding and quality control and/or the degradation of misfolded proteins (38). Therefore, the secretion and *N*-glycosylation for IgG1 in silkworm larvae were investigated using molecular chaperone-assisted translation. Abundant expression of HC and LC, controlled by polyhedrin and p10 promoters, respectively, was achieved in the silkworm larvae. Using the molecular chaperones CRT, CNX and BiP, increased IgG1 secretion levels up to five times higher than without the assistance of chaperones. The total yield of recombinant 29IJ6 IgG was 160.3 mg/larva following CRT coexpression. Thus, these chaperones had significant effects on IgG1 folding and assembly during post-translational modification. There may be two distinct chaperone systems in the silkworm ER, one comprising BiP, PDI and GrP94; the other ERp57, CNX and CRT (11). Therefore, coexpression of both chaperones might help in improving IgG1 production in silkworm. However, coexpression using combinations of CRT with other chaperones had little or no effect on IgG1 secretion in this model. Additionally, the amount of IgG1 secretion was decreased by the injection of high levels of CRT bacmids. CRT and CNX are clearly involved in retaining influenza hemagglutinin fragments in the ER (39). For human thyrotropin receptor (TSHR),

belonging to the G protein coupled receptor family, overexpressed CRT or CNX protected TSHR from being degraded immediately after synthesis, but this protection had disappeared completely after 5 h (40). In addition, when BiP was overexpressed the formation of correctly folded human thyroperoxidase (hTPO) decreased 2.5-fold after 5 h. The increased binding rate of BiP did not enhance the folding of the protein but rather led to its degradation and thus confirmed that BiP had negative effects on the folding of hTPO (41).

Most mammalian recombinant glycoproteins produced by insect cell or larval expression systems are produced with mannose-terminated glycans or other less complete structures, compared with the native protein produced in the original tissues (42). Although the *N*-linked glycans of the IgG1 produced in the present study were dominated by paucimannose structures, small amounts of GlcNAc residues linked to the Man α 1,3 branch were detected. As a nascent glycoprotein passes through the ER and Golgi apparatus, enzymes trim and add different sugars to this *N*-linked glycan. Therefore, we tested for any *N*-glycosylation differences in the IgG1 produced using molecular chaperone enhancement. This tested whether the trimming and terminal glycosylation capacity in Golgi apparatus was sufficient for increased IgG1 production, such as an increase in high-mannose structures and disappearance of terminal GlcNAc residues. However, the compositions of the *N*-linked glycans were no different from those produced without using molecular chaperones. This suggests that *N*-glycosylation was being controlled by a regulatory function in the Golgi apparatus even though the throughput of 296IJ6 IgG was increased following the coexpression of molecular

chaperones. These modification steps can vary in mammalian and insect hosts leading to differences in the structures of *N*-linked glycans (5).

In the case of β 1,3*N*-acetylglucosaminyltransferase 2 expressed in silkworm larvae, *N*-linked glycans with a terminal Gal and bisecting GlcNAc residues were detected (43). However, for IgG1 expression, paucimannosidic *N*-linked structures were predominant in the present study. Antibodies are *N*-glycosylated on the C_H2 domain of the Fc fragment at the Asn297 residue. *N*-glycosylation of the Fc domain of recombinant IgG produced in CHO and NS0 cells is mainly characterized by core-fucosylated complex type structures with low levels of galactosylation and sialylation (1). Increased terminal sialylation can increase the serum half-life of many proteins (44). However, Fc sialylation has both positive and negative effects on antibody functions (45–47). Increased sialylation of Fc glycans results in decreased Antibody-dependent cellular cytotoxicity (ADCC) activity of IgGs as terminal sialylation negatively affects antibody binding to the Fc γ RIIIa receptor (46, 47). In addition, increased sialylation can result in decreased binding to certain immobilized or cell surface expressed antigens (43). On the other hand, the effect of high mannose type Fc glycans on the serum half-life of IgGs can vary according to the antibody concerned, with the mechanism not yet resolved (45, 48, 49). Therefore, if the glycosylation pathways could be improved by the coexpression of *N*-acetylglucosaminyltransferase, galactosyltransferase and sialyltransferase, silkworm larvae would prove a useful host system for producing human antibodies.

ACKNOWLEDGMENTS

This work was supported by the Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN), Japan and by Grants-in-Aid for Scientific Research (B) (2137005) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References and Notes

- (1) Jefferis, R. Glycosylation of recombinant antibody therapeutics. *Biotechnol. Prog.* **2005**, *21*, 11–16.
- (2) Schirrmann, T.; Al-Halabi, L.; Dübel, S.; Hust, M. Production systems for recombinant antibodies. *Front. Biosci.* **2008**, *13*, 4576–4594.
- (3) Hsu, T.A.; Eiden, J.J.; Bourgarel, P.; Meo, T.; Betenbaugh, M.J. Effect of co-expressing chaperone BiP on functional antibody production in the baculovirus system. *Protein Expr. Purif.* **1994**, *5*, 595–603.
- (4) Jarvis, D.L.; Garcia, A. Biosynthesis and processing of the *Autographa californica* nuclear polyhedrosis virus gp64 protein. *Virology* **1994**, *205*, 300–313.
- (5) Ailor, E.; Betenbaugh, M.J. Modifying secretion and post-translational processing in insect cells. *Curr. Opin. Biotechnol.* **1999**, *10*, 142–145.
- (6) Hasemann, C.A.; Capra, J.D. High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system. *Proc. Natl. Acad. Sci. U S A* **1990**, *87*, 3942–3946.

- 379 (7) Kato, K.; Kamiya, Y. Structural views of glycoprotein–fate determination in cells.
380 *Glycobiology* **2007**, *17*, 1031–1044.
- 381 (8) Kamiya, Y.; Kato, K. Sugar recognition by intracellular lectins that determine the
382 fates of glycoproteins. *Trends Glycosci. Glycotech.* **2006**, *18*, 231–244.
- 383 (9) Ruddock, L.W.; Molinari, M. *N*-glycan processing in ER quality control. *J. Cell*
384 *Sci.* **2006**, *119*, 4373–4380.
- 385 (10) Moremen, K.W.; Molinari, M. *N*-linked glycan recognition and processing: the
386 molecular basis of endoplasmic reticulum quality control. *Curr. Opin. Struct. Biol.*
387 **2006**, *16*, 592–599.
- 388 (11) Molinari, M.; Helenius, A. Chaperone selection during glycoprotein translocation
389 into the endoplasmic reticulum. *Science* **2000**, *288*, 331–333.
- 390 (12) Hammond, C.; Helenius, A. Folding of VSV G protein: sequential interaction
391 with BiP and calnexin. *Science* **1994**, *266*, 456.
- 392 (13) Braakman, I.; Hoover-Litty, H.; Wagner, K.R.; Helenius, A. Folding of influenza
393 hemagglutinin in the endoplasmic reticulum. *J. Biol. Chem.* **1991**, *114*, 401–411.
- 394 (14) Melnick, J.; Dul, J.L.; Argon, Y. Sequential interaction of the chaperones BiP and
395 GRP94 with immunoglobulin chains in the endoplasmic reticulum. *Nature* **1994**,
396 *370*, 373–375.
- 397 (15) Molinari, M.; Helenius, A. Glycoproteins form mixed disulphides with
398 oxidoreductases during folding in living cells. *Nature* **1999**, *402*, 90–93.
- 399 (16) Cabrera, G.; Cremata, J.A.; Valdes, R.; Garcia, R.; Gonzalez, Y.; Montesino, R.;
400 Gomez, H.; Gonzalez, M. Influence of culture conditions on the *N*-glycosylation

of a monoclonal antibody specific for recombinant hepatitis B surface antigen.

Biotechnol. Appl. Biochem. **2005**, *41*, 67–76.

- (17) Park, E.Y.; Ishikiriya, M.; Nishina, T.; Kato, T.; Yagi, H.; Kato, K.; Ueda, H. Human IgG1 expression in silkworm larval hemolymph using BmNPV bacmids and its *N*-linked glycan structure. *J. Biotechnol.* **2009**, *139*, 108–114.

- (18) Nakajima, M.; Kato, T.; Kanamasa, S.; Park, E.Y. Molecular chaperone-assisted production of human α -1,4-*N*-acetylglucosaminyltransferase in silkworm larvae using recombinant BmNPV bacmids. *Mol. Biotechnol.* **2009**, in press. DOI 10.1007/s12033-009-9174-8

- (19) Tomiya, N.; Kurono, M.; Ishihara, H.; Tejima, S.; Endo, S.; Arata, Y.; Takahashi, N. Analyses of *N*-linked oligosaccharides using a two-dimensional mapping technique. *Anal. Biochem.* **1987**, *163*, 489–499.

- (20) Nakagawa, H.; Kawamura, Y.; Kato, K.; Shimada, I.; Arata, Y.; Takahashi, N. Identification of neutral and sialyl *N*-linked oligosaccharide structures from human serum glycoproteins using three kinds of high-performance liquid chromatography. *Anal. Biochem.* **1995**, *226*, 130–138.

- (21) Takahashi, N.; Nakagawa, H.; Fujikawa, K.; Kawamura, Y.; Tomiya, N. Three-dimensional elution mapping of pyridylaminated *N*-linked neutral and sialyl oligosaccharides. *Anal. Biochem.* **1995**, *226*, 139–146.

- (22) Takahashi, N.; Kato, K. GALAXY (Glycoanalysis by the three axes of MS and Chromatography): a web application that assists structural analysis of *N*-glycans, *Trends Glycosci. Glycotechnol.* **2003**, *15*, 235–251.

- 423 (23) Yagi, H.; Takahashi, N.; Yamaguchi, Y.; Kimura, N.; Uchiyama, K.; Kannagi, R.;
 424 Kato, K. Development of structural analysis of sulfated *N*-glycans by
 425 multidimensional high performance liquid chromatography mapping methods.
 426 *Glycobiology* **2005**, *15*, 1051–1060.
- 427 (24) Theilman, D.A.; Stewart, S. Molecular analysis of the trans-activating IE-2 gene
 428 of *Orgyia pseudotsugata* multicapsid nuclear polyhedrosis virus. *Virology* **1992**,
 429 *187*, 84–96.
- 430 (25) Werner, R.G.; Kopp, K.; Schlueter, M. Glycosylation of therapeutic protein in
 431 different production systems. *Acta. Paediatr. Suppl.* **2007**, *96*, 17–22.
- 432 (26) Kamoda, S.; Kakehi, K. Evaluation of glycosylation for quality assurance of
 433 antibody pharmaceuticals by capillary electrophoresis. *Electrophoresis* **2008**, *29*,
 434 3595–3604.
- 435 (27) Rahman, M.M.; Gopinathan, K.P. Systemic and in vitro infection process of
 436 *Bombyx mori* nucleopolyhedrovirus. *Vir. Res.* **2004**, *101*, 109–118.
- 437 (28) Park, E.Y.; Kageshima, A.; Kwon, M.S.; Kato, T. Enhanced production of
 438 secretory β 1,3-*N*-acetylglucosaminyltransferase 2 fusion protein into hemolymph
 439 of *Bombyx mori* larvae using recombinant BmNPV bacmid integrated signal
 440 sequence. *J. Biotechnol.* **2007**, *129*, 681–688.
- 441 (29) Shuler, M. L.; Wood, H. A.; Granados, R. R. Baculovirus Expression System
 442 and Biopesticides. Wiley-Liss, Inc., New York, **1995**.
- 443 (30) Kato, T.; Park, E.Y. Specific expression of
 444 GFP_{uv}- β 1,3-*N*-acetylglucosaminyltransferase 2 fusion protein in fat body of

- 445 *Bombyx mori* silkworm larvae using signal peptide. *Biochem. Biophys. Res.*
 446 *Commun.* **2007**, 359, 543–548
- 447 (31) Ellgaard, L.; Molinari, M.; Helenius, A. Setting the standards: quality control in
 448 the secretory pathway. *Science* **1999**, 286, 1882–1888.
- 449 (32) Kato, T.; Murata, T.; Usui, T.; Park, E.Y. Improvement of the production of
 450 GFP_{uv}-β1,3-*N*-acetylglucosaminyltransferase 2 fusion protein using a molecular
 451 chaperone-assisted insect-cell-based expression system, *Biotechnol. Bioeng.*
 452 **2005**, 89, 424–433.
- 453 (33) Ishikiriya, M.; Nishina, T.; Kato, T.; Ueda, H.; Park, E.Y. Human single-chain
 454 antibody expression in the hemolymph and fat body of silkworm larvae and
 455 pupae using BmNPV bacmids. *J. Biosci. Bioeng.* **2009**, 107, 67–72.
- 456 (34) Dojima, T.; Nishina, T.; Kato, T.; Ueda, H.; Park, E.Y. Comparative study of
 457 affinity-tagged proteins for efficient purification of recombinant secretory
 458 protein expressed in silkworm larval hemolymph. *Biotechnol. Bioprocess Eng.*
 459 **2009**, 14, 281–287.
- 460 (35) Demarest, S.J.; Glaser, S.M. Antibody therapeutics, antibody engineering and the
 461 merits of protein stability. *Curr. Opin. Drug Discov. Devel.* **2008**, 11, 675–687.
- 462 (36) Meunier, L.; Usherwood, Y.K.; Chung, K.T.; Hendershot, L.M. A subset of
 463 chaperones and folding enzymes form multiprotein complexes in endoplasmic
 464 reticulum to bind nascent proteins. *Mol. Biol. Cell* **2002**, 13, 4456–4469.
- 465 (37) Whiteley, E.M.; Hsu, T.A.; Betenbaugh, M.J. Thioredoxin domain
 466 non-equivalence and anti-chaperone activity of protein disulfide isomerase

- 467 mutants in vivo. *J. Biol. Chem.* **1997**, 272, 22556–22563.
- 468 (38) Yoshida, Y.; Chiba, T.; Tokunaga, F.; Kawasaki, H.; Iwai, K.; Suzuki, T.; Ito, Y.;
 469 Matsuoka, K.; Yoshida, M.; Tanaka, K.; Tai, T. E3 ubiquitin ligase that
 470 recognizes sugar chains. *Nature* **2002**, 418, 438–442.
- 471 (39) Zhang, J.X.; Braakman, I.; Matlack, K.E.S.; Helenius, A. Quality control in the
 472 secretory pathway: The role of calreticulin, calnexin and BiP in the retention of
 473 glycoproteins with C-terminal truncations. *Mol. Biol. Cell* **1997**, 8, 1943–1954.
- 474 (40) Siffroi-Fernandez, S.; Giraud, A.; Lanet, J.; Franc, J.L. Association of the
 475 thyrotropin receptor with calnexin, calreticulin and BiP, *Eur. J. Biochem.* **2002**,
 476 269, 4930–4937.
- 477 (41) Le Fourn, V.; Siffroi-Fernandez, S.; Ferrand, M.; Franc, J.L. Competition
 478 between calnexin and BiP in the endoplasmic reticulum can lead to the folding or
 479 degradation of human thyroperoxidase. *Biochem.* **2006**, 45, 7380–7388.
- 480 (42) Luckow, V.A. In: Shuler, M. L.; Wood, H. A.; Granados, R. R (Eds) Baculovirus
 481 Expression System and Biopesticides, Wiley–Liss, New York, **1995**, pp. 51–90.
- 482 (43) Dojima, T.; Nishina, T.; Kato, T.; Uno, T.; Yagi, H.; Kato, K.; Park, E.Y.
 483 Comparison of the *N*-linked glycosylation of human
 484 β 1,3-*N*-acetylglucosaminyltransferase 2 expressed in insect cells and silkworm
 485 larvae. *J. Biotechnol.* **2009**, in press. DOI: 10.1016/j.jbiotec.2009.06.013
- 486 (44) Wright, A.; Morrison, S.L. Effect of glycosylation on antibody function:
 487 implications for genetic engineering. *Trends Biotechnol.* **1997**, 15, 26–32.
- 488 (45) Raju, T.S. Terminal sugars of Fc glycans influence antibodies effector functions

489 of IgGs. *Curr. Opin. Immunol.* **2008**, *20*, 471–478.

490 (46) Scallon, B.J.; Tam, S.H.; McCarthy, S.G.; Cai, A.; Raju, T.S. High levels of
 491 sialylated Fc glycans in immunoglobulin G molecules can adversely impact
 492 functionality. *Mol. Immunol.* **2007**, *44*, 1524–1534.

493 (47) Kaneko, Y.; Nimmerjahn, F.; Ravetch, J.V. Anti-inflammatory activity of
 494 immunoglobulin G resulting from Fc sialylation. *Science* **2006**, *313*, 670–673.

495 (48) Wright, A.; Sato, Y.; Okada, T.; Chang, K.; Endo, T.; Morrison, S. In vivo
 496 trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of
 497 differing structure. *Glycobiol.* **2000**, *10*, 1347–1355.

498 (49) Millward, T.A.; Heitzmann, M.; Bill, K.; Langle, U.; Schumacher, P.; Forrer, K.
 499 Effect of constant and variable domain glycosylation on pharmacokinetics of
 500 therapeutic antibodies in mice. *Biologicals*, New York, **2008**, *36*, 41–47.

Figure Legends

Figure 1. Western blot analysis of secreted 29IJ6 IgG in silkworm larval hemolymph under reducing (A) and nonreducing conditions (B). Lane 1, IgG expression without molecular chaperone assistance; lanes 2–6, CNX-, BiP-, ERp57-, CRT- and Hsp70-assisted expression of IgG. H₂L₂, H₂L and H₂ in (B) denote the complete IgG, heavy chain dimer–light chain and heavy chain dimer, respectively.

Figure 2. Molecular chaperone-assisted secretion of IgG in silkworm larval hemolymph. Control indicates IgG expression without chaperone-coexpression. Error bars denote standard deviation.

Figure 3. Multiple molecular chaperones-assisted secretion of IgG in silkworm larval hemolymph. Control indicates IgG expression without chaperone coexpression. Error bars denote standard deviations.

Figure 4. Effects of the injected amounts of rBmNPV(*ie*)-CP⁺/CRT bacmid on IgG1 secretion in silkworm larval hemolymph. Error bars denote standard deviations.

Table 1 Structures of *N*-linked glycans on IgG expressed in silkworm

	GU (ODS)	GU (Amide)	MS value [M+H] ⁺	Structure
a	10.4	3.5	973	$\begin{array}{c} \text{Man}\alpha 1, \\ \text{Man}\beta 1-4\text{GlcNAc}\beta 1-4\text{GlcNAc} \end{array} \begin{array}{c} \text{Fuc}\alpha 1 \\ \text{6} \end{array}$
b	10.3	4.8	1135	$\begin{array}{c} \text{Man}\alpha 1, \\ \text{Man}\alpha 1', \\ \text{Man}\beta 1-4\text{GlcNAc}\beta 1-4\text{GlcNAc} \end{array} \begin{array}{c} \text{Fuc}\alpha 1 \\ \text{6} \end{array}$
c	10.3	5.2	1338	$\begin{array}{c} \text{Man}\alpha 1, \\ \text{GlcNAc}\beta 1-2 \text{ Man}\alpha 1', \\ \text{Man}\beta 1-4\text{GlcNAc}\beta 1-4\text{GlcNAc} \end{array} \begin{array}{c} \text{Fuc}\alpha 1 \\ \text{6} \end{array}$

Table 2 Relative quantity of *N*-linked glycan composition on IgG expression in silkworm

Structure	Larvae						Pupae
	—	CNX	CRT	BiP	ERp57	Hsp70	—
a	47.4	49.1	46.1	45.7	44.4	46.0	18.6
b	28.5	31.7	33.2	31.3	32.8	32.5	33.5
c	3.4	3.7	3.8	3.7	4.1	4.0	14.6
others	20.7	15.5	16.9	19.3	18.7	17.5	33.3

Fig. 4, Dojima et al.